The New York Times just had an article about the Drug Avandia. It states that a Congressional committee hearing next Wednesday will try to determine whether federal regulators paid sufficient attention to potential risks of the diabetes drug Avandia. One witness, scheduled to appear at the hearing, claims that Avandia’s maker, GlaxoSmithKline, attempted to silence his criticism of the drug. John B. Buse, a nationally recognized diabetes specialist, says that Glaxo engaged in tactics to intimidate the doctor to keep him from going public with his concerns.
Comments are closed.